Deferasirox (Exjade®, ICL670) treatment of inadequately chelated β-thalassemia patients from the Middle East:: The ESCALATOR trial.

被引：0
|
作者：
Taher, A
El-Beshlawy, A
Al Jefri, A
El Alfy, M
Al Zir, K
Daar, S
Al-Damanhouri, G
Hadler, D
Krahn, U
机构：
[1] Amer Univ Beirut, Chron Care Ctr, Beirut, Lebanon
[2] Cairo Univ, Cairo, Egypt
[3] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia
[4] Ain Shams Univ, Cairo, Egypt
[5] Natl Thalassemia Ctr, Damascus, Syria
[6] Sultan Qaboos Univ, Muscat, Oman
[7] King Abdulaziz Univ Hosp, Jeddah, Saudi Arabia
[8] Novartis Pharma AG, Basel, Switzerland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3840
引用
收藏
页码：40B / 41B
页数：2
相关论文
共 50 条
  • [21] Sustained protection from labile plasma iron (LPI) with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in iron-overloaded β-thalassemia patients.
    Daar, S.
    Taher, A.
    Pathare, A.
    Nick, H.
    Krahn, U.
    Hadler, D.
    Capdeville, Renaud
    BLOOD, 2006, 108 (11) : 503A - 503A
  • [22] Summary of long-term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade®, ICL670).
    Bennett, W.
    Ponticelli, C.
    Piga, A.
    Kattamis, A.
    Glimm, E.
    Ford, J.
    BLOOD, 2006, 108 (11) : 30B - 30B
  • [23] Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD):: Comparison between deferasirox (Exjade®, ICL670) and deferoxamine (DFO).
    Vichinsky, E
    Fischer, R
    Pakbaz, Z
    Onyekwere, O
    Porter, J
    Swerdlow, P
    Coates, T
    Lane, P
    Files, B
    Mueller, BU
    Coïc, L
    Forni, G
    Abetz, L
    Baladi, JF
    Ressayre-Djaffer, C
    Gathmann, I
    Alberti, D
    Marks, P
    BLOOD, 2005, 106 (11) : 656A - 657A
  • [24] Iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis.
    Angelucci, E
    Turlin, B
    Canatan, D
    Mangiagli, A
    De Sanctis, V
    Meddeb, B
    Rose, C
    Soulieres, D
    Cunningham, M
    Gattermann, N
    Ressayre-Djaffer, C
    Rabault, B
    Ford, J
    BLOOD, 2005, 106 (11) : 757A - 758A
  • [25] Long-term efficacy and safety with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in pediatric patients
    Piga, Antonio
    Vichinsky, Elliott
    Forni, Gian Luca
    Kilinc, Yurdanur
    Maseruka, Henry
    Kattamis, Antonios
    BLOOD, 2007, 110 (11) : 815A - 815A
  • [26] Inflammation and oxidant-stress in β-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial
    Walter, Patrick B.
    Macklin, Eric A.
    Porter, John
    Evans, Patricia
    Kwiatkowski, Janet L.
    Neufeld, Ellis J.
    Coates, Thomas
    Giardina, Patricia J.
    Vichinsky, Elliott
    Olivieri, Nancy
    Alberti, Daniele
    Holland, Jaymes
    Harmatz, Paul
    Neufeld, Ellis
    Cunningham, Melody
    Braunstein, Jennifer
    Cohen, Alan R.
    Manno, Catherine S.
    Hillman, Debra
    Martin, Marie
    Singer, Sylvia
    Walter, Patrick
    Sweeters, Nancy
    Pang, Eun-Ha
    Foote, Dru
    Nurse, Thalassemia
    Warr, Gladys
    Lui, Annie
    Weihing, Robert
    Wymbs, Kerry
    Merson, Laura
    Muraca, Giulia
    Stamplecoski, Melissa
    Cummins, Michelle
    Grady, Robert W.
    Kleinert, Dorothy
    Mait, Jeffrey E.
    Nathan, David
    Peterson, Charles
    Wright, Libby
    McKinlay, Sonja
    Macklin, Eric
    McCarthy, Ellen
    HAEMATOLOGICA, 2008, 93 (06) : 817 - 825
  • [27] Long-term treatment with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, is effective in patients with transfusion-dependent anemias
    Cappellini, Maria Domenica
    Vichinsky, Elliott
    Galanello, Renzo
    Piga, Antonio
    Williamson, Paul
    Porter, John B.
    BLOOD, 2007, 110 (11) : 816A - 816A
  • [28] Effect of iron chelation therapy with deferasirox (Exjade®, ICL670) or deferoxamine on hepatocellular inflammation and liver function in patients with transfusion-dependent anemia
    Deugnier, Y.
    Turlin, B.
    Ropert-Bouchet, M.
    Rabault, B.
    Brissot, P.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S79 - S80
  • [29] Development of lens opacities with peculiar characteristics in patients affected by thalassemia major on chelating treatment with deferasirox (ICL670) at the Pediatric Clinic in Monza, Italy
    Masera, N.
    Rescaldani, C.
    Azzolini, M.
    Vimercati, C.
    Tavecchia, L.
    Masera, G.
    De Molfetta, V.
    Arpa, P.
    HAEMATOLOGICA, 2007, 93 (01) : E9 - E10
  • [30] Deferasirox (Exjadeg®, ICL670) is effective and tolerable in β-thalassemia patients with high iron burden and history of inadequate chelation therapy.
    Taher, A.
    El-Beshlawy, A.
    Al Jefri, A.
    Elalfy, M.
    Al Zir, K.
    Daar, S.
    Darnanhouri, G.
    Krahn, U.
    Hadler, D.
    BLOOD, 2006, 108 (11) : 32B - 32B
12345